NYSE · Financial Statements
Arcus Biosciences, Inc. (RCUS) Financial Statements
$24.41
NYSE: RCUS
Market Cap $3.07B
Overview Financials Dividend
Arcus Biosciences, Inc. most recently reported annual revenue of $247.0M, a net loss of $353.0M. Revenue grew at an average annual rate of 25.9% over the last 5 fiscal years. See the full income statement, balance sheet, and cash flow statement below, plus valuation and return ratios.
Annual Financials (USD)
Metric 2021 2022 2023 2024 2025
Revenue $383.0M $112.0M $117.0M $258.0M $247.0M Operating Profit $54.0M $-280.0M $-340.0M $-330.0M $-386.0M Net Profit $53.0M $-267.0M $-307.0M $-283.0M $-353.0M EPS $0.71 $-3.71 $-4.15 $-3.14 $-3.29 Op Margin 14.1% -250.0% -290.6% -127.9% -156.3%
Balance Sheet (USD)
Metric 2021 2022 2023 2024 2025
Total Assets $1.6B $1.3B $1.1B $1.1B $1.1B Total Liabilities $750.0M $688.0M $633.0M $665.0M $508.0M Cash $148.0M $206.0M $127.0M $150.0M $222.0M Borrowings $122.0M $120.0M $11.0M $60.0M $112.0M
Cash Flow (USD)
Metric 2021 2022 2023 2024 2025
Operating Cash Flow $-256.0M $438.0M $-306.0M $-170.0M $-482.0M Investing Cash Flow $-30.0M $-419.0M $170.0M $-90.0M $64.0M Financing Cash Flow $0 $10.0M $8.0M $2.0M $0 Net Cash Flow $-26.0M $58.0M $-79.0M $23.0M $72.0M Free Cash Flow $-282.0M $432.0M $-330.0M $-176.0M $-484.0M
Valuation & Return Ratios
Metric Value PEG Ratio 0.30 EV / EBITDA -7.25 FCF Yield -15.45% Quick Ratio 3.82 Interest Coverage -21.13 Return 1Y 190.25% Return 3Y 40.85% Return 5Y 3.83%
Data for information only, not investment advice. Figures may be delayed or inaccurate; verify against company filings. See our disclaimer .